BioStock: Takeda’s milestone payment strengthens BioInvent’s business model

BioInvent is reinforcing its position as a partner in antibody development. This was made evident as global pharmaceutical giant Takeda has initiated a phase III trial with mezagitamab (TAK-079) – an antibody originally identified using BioInvent’s proprietary n-CoDeR platform. As a result, a milestone payment of USD 1 million to BioInvent has been triggered.

Read the article at biostock.se:

https://www.biostock.se/en/2025/04/takedas-milestone-payment-strengthens-bioinvents-business-model/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/